title: Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - NO.
authors.affiliation: Department of Neurology, University of California-San Francisco, San Francisco, CA, USA carla.francisco@ucsf.edu.
authors.forename: Carla
authors.initials: C
authors.lastname: Francisco
authors.affiliation: Department of Neurology, University of California-San Francisco, San Francisco, CA, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Graves
authors.affiliation: Department of Neurology, University of California-San Francisco, San Francisco, CA, USA.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Waubant
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000628:therapy; D010372:Pediatrics
chemical_list: D007155:Immunologic Factors